Tseng PT, Chen MH, Liang CS. Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia. World J Psychiatry 2022; 12(8): 1102-1104 [PMID: 36158309 DOI: 10.5498/wjp.v12.i8.1102]
Corresponding Author of This Article
Chih-Sung Liang, MD, Assistant Professor, Attending Doctor, Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, No. 60 Xinmin Road, Beitou District, Taipei 112, Taiwan. lcsyfw@gmail.com
Research Domain of This Article
Psychiatry
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Aug 19, 2022; 12(8): 1102-1104 Published online Aug 19, 2022. doi: 10.5498/wjp.v12.i8.1102
Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia
Ping-Tao Tseng, Mu-Hong Chen, Chih-Sung Liang
Ping-Tao Tseng, Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 804, Taiwan
Mu-Hong Chen, Department of Psychiatry, Taipei Veterans General Hospital, Taipei 112, Taiwan
Chih-Sung Liang, Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei 112, Taiwan
Author contributions: Tseng PT and Chen MH designed research; Chen MH and Liang CS performed research; Tseng PT and Liang CS analyzed data; Tseng PT wrote the letter; and Chen MH and Liang CS revised the letter.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chih-Sung Liang, MD, Assistant Professor, Attending Doctor, Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, No. 60 Xinmin Road, Beitou District, Taipei 112, Taiwan. lcsyfw@gmail.com
Received: September 4, 2021 Peer-review started: September 4, 2021 First decision: November 8, 2021 Revised: November 19, 2021 Accepted: July 11, 2022 Article in press: July 11, 2022 Published online: August 19, 2022 Processing time: 347 Days and 7.5 Hours
Abstract
We read the impressive review article “Clozapine resistant schizophrenia: Newer avenues of management” with great enthusiasm and appreciation. The author believes that preventing clozapine resistance from developing may be the most effective treatment strategy for patients with clozapine-resistant schizophrenia (CRS), and optimizing clozapine treatment is a key component. Disentangling the differences between treatment-resistant schizophrenia and CRS is important for studies addressing treatment strategies for these difficult-to-treat populations.
Core Tip: A diagnosis of clozapine-resistant schizophrenia (CRS) is made after administering an adequate trial of clozapine and excluding “pseudo-resistance” in patients who have been diagnosed with treatment-resistant schizophrenia (TRS). Disentangling the differences between TRS and CRS is important point for studies addressing treatment strategies for patients with CRS.
